Mir Hashim
2021
In 2021, Mir Hashim earned a total compensation of $5M as Chief Scientific Officer at Rani Therapeutics Holdings, a 694% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $300,000 |
|---|---|
| Option Awards | $2,010,118 |
| Salary | $396,923 |
| Stock Awards | $2,300,256 |
| Total | $5,007,297 |
Hashim received $2.3M in stock awards, accounting for 46% of the total pay in 2021.
Hashim also received $300K in non-equity incentive plan, $2M in option awards and $396.9K in salary.
Rankings
In 2021, Mir Hashim's compensation ranked 2,615th out of 12,415 executives tracked by ExecPay. In other words, Hashim earned more than 78.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,615 out of 12,415 | 79th |
Division Manufacturing | 1,034 out of 5,505 | 81st |
Major group Chemicals And Allied Products | 401 out of 2,375 | 83rd |
Industry group Drugs | 351 out of 2,096 | 83rd |
Industry Pharmaceutical Preparations | 230 out of 1,546 | 85th |
Source: SEC filing on April 13, 2022.
Hashim's colleagues
We found three more compensation records of executives who worked with Mir Hashim at Rani Therapeutics Holdings in 2021.